Boundless Inc

B.E.S.T. PROGRAM (BOUNDLESS EXPERIENCES FOR SUCCESSFUL TRANSITIONS) - SUMMARY OF PROJECT-B.E.S.T. PROGRAM IS A COMPREHENSIVE APPROACH TO WRAPPING SUPPORTS AROUND INDIVIDUALS AGES 14-29 WHO HAVE AUTISM SPECTRUM DISORDERS OR CO-OCCURRING SED/SMI WITH IDD DURING THE CRITICAL PERIOD OF TRANSITION FROM YOUTH TO YOUNG ADULTHOOD. THIS PROGRAM WILL PROVIDE INTENSIVE CARE COORDINATION DURING THIS CRITICAL PERIOD OF LIFE AND OFFER TWO ACUITY TRACKS TO THESE INDIVIDUALS. ACUITY TRACK 1 IS FOCUSED ON HIGH-NEED, LOWER FUNCTIONING INDIVIDUALS WHO RECEIVED 1:1 SUPPORTS THROUGHOUT CHILDHOOD, OFTEN INCLUDING ABA, AND THEY AND THEIR FAMILIES FIND THAT THIS LEVEL OF CARE IS SUDDENLY UNAVAILABLE UPON REACHING ADULTHOOD. ACUITY TRACK 2 IS FOCUSED ON SERVING HIGHER FUNCTIONING INDIVIDUALS WITH AUTISM SPECTRUM DISORDERS WHO DO NOT FIT "NEATLY" IN THE TRADITIONAL IDD SYSTEM OF CARE, BUT WHO NEED GREATER SUPPORT DURING THIS TRANSITION PERIOD IN ORDER TO ENSURE SUCCESS IN ADULTHOOD THAN THE TYPICAL COMMUNITY MENTAL HEALTH SYSTEM CAN OFFER THROUGH MOST OUTPATIENT SETTINGS. PROJECT NAME-B.E.S.T. (BOUNDLESS EXPERIENCES FOR SUCCESSFUL TRANSITIONS) POPULATIONS TO BE SERVED- YOUTH AND YOUNG ADULTS WITH ASD & CO-OCCURRING SED/SMI WITH IDD STRATEGIES/ INTERVENTIONS- HIGH INTENSITY CARE COORDINATION, ACUITY-TIERED DAY TREATMENT PROGRAMS, OUTPATIENT POPULATION-SPECIFIC MENTAL HEALTH TREATMENTS, WORK READINESS AND INDEPENDENT LIVING CLINICAL SUPPORT SERVICES & PSYCHOEDUCATION, POPULATION-SPECIFIC PEER SUPPORT SERVICES, POPULATION-SPECIFIC CRISIS INTERVENTION & MOBILE CRISIS RESPONSE, LINKAGE AND COORDINATION WITH THE DEVELOPMENTAL DISABILITIES SYSTEMS OF CARE. PROJECT GOAL-INCREASE THE INCIDENCE OF SUCCESSFUL TRANSITION TO ADULTHOOD FOR YOUTH AND YOUNG ADULTS WITH ASD OR CO-OCCURRING SED/SMI W/IDD BY IMPROVING SYSTEM COORDINATION AND PROVIDING SPECIALIZED COMPREHENSIVE CARE. OBJECTIVE 1-95% OF PARTICIPANTS AGES 22-29 WILL BE EITHER EMPLOYED, ENROLLED IN HIGHER EDUCATION, OR ENGAGED IN A DAILY ACTIVITY THAT THE INDIVIDUAL REPORTS AS MEANINGFUL. OBJECTIVE 2-90% OF PARTICIPANTS AGES 22-29 WILL LIVE IN EITHER A NATURAL FAMILY SETTING OR A SETTING WITH 3 OR LESS NON-FAMILY MEMBER INDIVIDUALS (I.E. COMMUNITY INTEGRATED, NOT FACILITY PLACEMENTS) OBJECTIVE 3-PARTICIPANTS, IN AGGREGATE, WILL REPORT A PERSONAL OUTCOMES MEASURES AVERAGE SCORE OF 30 OR HIGHER OBJECTIVE 4-95% OF PARTICIPANTS AGES 14-21 WILL SUCCESSFULLY MAINTAIN PLACEMENT WITHIN THEIR FAMILY/CAREGIVER HOME (I.E. AVOIDING CUSTODY TRANSITIONS)

AEROSOL VENTILATION TO REDUCE VENTILATOR INDUCED LUNG INJURY - PROJECT SUMMARY MECHANICAL VENTILATION (MV) IS USED IN AN ICU SETTING WHEN RESPIRATORY FAILURE OCCURS FOR A VARIETY OF REASONS, INCLUDING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). THE MORTALITY OF SEVERE ARDS APPROACHES 50% AND EVEN THOSE THAT SURVIVE TYPICALLY REQUIRE MV AND SUFFER LONG-TERM ADVERSE IMPACTS ON THEIR LUNG FUNCTION. THE AGGRESSIVE VENTILATOR SETTINGS USED DURING MC APPLY STRONG MECHANICAL FORCES DURING VENTILATION THAT CAN LEAD TO VENTILATOR-INDUCED LUNG INJURY (VILI) VIA PHYSICAL DISRUPTION OF THE TISSUES AND CELLS AND ACTIVATION OF CYTOTOXIC AND INFLAMMATORY RESPONSES. ALTERNATIVES TO MV, SUCH AS ECMO (EXTRACORPOREAL MEMBRANE OXYGENATION), CAN EFFICIENTLY PERFORM VENTILATION AND OXYGENATION, IS EXORBITANTLY EXPENSIVE, REQUIRES HIGHLY SPECIALIZED TEAMS AND EQUIPMENT THAT IS NOT WIDELY AVAILABLE, AND CARRIES HIGH RISKS OF STROKE, BLEEDING, AND THROMBOSIS. WE PROPOSE THAT AEROSOLIZING LIQUID PERFLUOROCARBONS (LPS) WITH THE INSPIRED AIR DURING MV WILL ACHIEVE MORE RAPID COOLING AND EFFICIENT GAS EXCHANGE, NEGATING THE NEED FOR HIGH VENTILATOR SETTINGS AND THUS REDUCING VILI. TO ACHIEVE THIS, BOUNDLESS SCIENCE IS DEVELOPING A BI-LIQUID AEROSOLIZED THERAPY (BAT) COUPLED TO A MECHANICAL VENTILATOR TO YIELD A BAT SYSTEM (BATS) TO INTRODUCE A FINE PERFLUOROCARBON MIST THAT SIMULTANEOUSLY COOLS THE LUNGS TO REDUCE INFLAMMATION WHILE ENHANCING OXYGEN DELIVERY TO OVERCOME PULMONARY DYSFUNCTION. OUR PRELIMINARY RESULTS INDICATE THAT BATS SUCCESSFULLY AND RAPIDLY COOLED ISOLATED PIG LUNGS TO 32°C. WE HYPOTHESIZE THAT BATS WILL ACHIEVE LOW POLYDISPERSITY OF MEDIAN AEROSOL DROPLET TO OBTAIN UNIFORM PULMONARY DISTRIBUTION AND CONSISTENT EFFICACY WHILE USING AN LP MIXTURE THAT ENHANCES CO2 EXHALATION AND THUS IMPROVE PATIENT OUTCOMES. AT THE SAME TIME, THE EVAPORATIVE COOLING IN THE EPITHELIUM WILL FURTHER REDUCE INFLAMMATION BEYOND THE INHERENT ANTI-INFLAMMATORY PROPERTIES OF THE LPS, WHILE LP RECYCLING WITHIN A STANDARD VENTILATOR WILL REDUCING COSTS AND MAKING IT COMMERCIALLY VIABLE FOR THE FIRST TIME. THE OBJECTIVE OF THIS PROPOSAL IS TO PROVIDE PROOF OF CONCEPT THAT BAT COUPLED WITH MV WILL INCREASE PULMONARY OXYGENATION (PAO2/FIO2) BY 50% WITHOUT CAUSING TRAUMA. WE WILL PROGRESS TOWARD THIS OBJECTIVE USING THE FOLLOWING SPECIFIC AIMS. AIM 1) DETERMINE THE OPTIMAL MIXTURE OF LPS THAT HAS LOW LEVEL CYTOTOXICITY AND PROVIDES THE HIGHEST ANTI-INFLAMMATORY EFFECTS IN VITRO. AIM 2) CREATE THE OPTIMAL DROPLET SIZE AND LP RATIO TO EFFECTIVELY INFILTRATE AND COOL ALVEOLI WITH AEROSOLIZED LP. AIM 3) EVALUATE THE OPTIMIZED AEROSOLIZED LP MIXTURE AND DROPLET SIZE FROM AIMS 1 AND 2 IN AN IN VIVO PORCINE MODEL OF ARDS. SUCCESSFUL RESULTS WILL NOT ONLY SHOW THE POTENTIAL OF BATS BUT WILL IMPORTANTLY PROVIDE THE NECESSARY DESIGN GUIDELINES TO DRIVE THE DEVELOPMENT OF A CLINICALLY AND COMMERCIALLY VIABLE SYSTEM.

ULTRASOUND ENHANCED EXTRACORPOREAL MEMBRANE OXYGENATION - PROJECT SUMMARY APPROXIMATELY 16,000 PATIENTS RECEIVED ARTIFICIAL PULMONARY SUPPORT VIA EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) IN 2019. DURING ECMO, HOLLOW FIBER MEMBRANE (HFM) GAS EXCHANGERS REQUIRE A SURFACE AREA OF ~2 M2 TO ACHIEVE THERAPEUTIC GAS TRANSFER; HOWEVER, THIS LARGE CONTACT AREA WITH THE BLOOD ACTIVATES THE COAGULATION CASCADE THAT REQUIRES SYSTEMIC ANTICOAGULATION FOR SUPPRESSION, USUALLY WITH HEPARIN. ALTHOUGH HEPARIN REDUCES THE FREQUENCY OF CLOTTING, IT DOES NOT EFFECTIVELY INHIBIT THE SURFACE DEPOSITION OF PLATELETS AND PROTEINS. THE CONSUMPTION OF THESE CRITICAL CLOTTING COMPONENTS, AS WELL AS CONTINUOUS ADMINISTRATION OF SYSTEMIC ANTICOAGULANT, RESULTS IN AN INCREASED RISK OF BLEEDING DURING ECMO AND INCREASES THE RISK OF COMPLICATIONS AND MORTALITY. WE PROPOSE THAT REDUCING THE SURFACE AREA OF THE HFM GAS EXCHANGER WILL LEAD TO LESS CLOTTING AND REQUIRE LESS ANTICOAGULANT USE, REDUCING THE INCIDENCE OF BOTH THROMBOSIS AND HEMORRHAGE. TO ACHIEVE THIS, BOUNDLESS SCIENCE IS DEVELOPING A NOVEL BLOOD OXYGENATION SYSTEM THAT USES ULTRASOUND TO DRAMATICALLY ENHANCE GAS TRANSFER EFFICIENCY, AND THEREBY REDUCE THE REQUIRED GAS EXCHANGER AREA. A SMALLER GAS EXCHANGER WILL INDUCE LESS CLOTTING AND REQUIRE LESS ANTICOAGULATION AND ASSOCIATED BLEEDING RISKS. AN ADDITIONAL BENEFIT IS THAT A SMALLER SURFACE AREA WILL ALLOW US TO DEVELOP A DRAMATICALLY SMALLER ECMO SYSTEM, OFFERING THE POTENTIAL FOR AMBULATORY ECMO. OUR INITIAL RESULTS WITH ULTRASOUND-ENHANCED ECMO (US-ECMO) SHOW THAT ULTRASOUND (US) ENHANCES THE RATE OF OXYGEN TRANSPORT ACROSS A PLANAR NANO-POROUS POLYPROPYLENE MEMBRANE BY 4–6.4-FOLD. WE HYPOTHESIZE THAT US ENHANCES TRANSPORT THROUGH TWO MECHANISMS. FIRST, THE ABSORPTION OF US TRAVELLING THROUGH THE BLOOD INDUCES A BULK FORCE, WHICH IN TURN GENERATES FLOW KNOWN AS BULK STREAMING. SECOND, US OSCILLATES GAS/BLOOD MENISCI AT THE MEMBRANE SURFACE, RAPIDLY MIXING THE BLOOD NEAR THE MEMBRANE IN A PROCESS KNOWN AS MICROSTREAMING. BLOOD MIXING FROM THESE MECHANISMS DISRUPTS THE BOUNDARY LAYER AT THE BLOOD-MEMBRANE INTERFACE, STEEPENING THE OXYGEN GRADIENT AND DRIVING FASTER DIFFUSION. THIS PROPOSAL SEEKS TO IDENTIFY THE US AND MEMBRANE CONFIGURATIONS THAT MAXIMIZE GAS EXCHANGE WITHIN CLINICALLY RELEVANT HFM. WE WILL CONSTRAIN US PARAMETERS TO AVOID BLOOD DAMAGE. WE WILL PROGRESS TOWARD THIS OBJECTIVE THROUGH THE FOLLOWING SPECIFIC AIMS. AIM 1) DETERMINE THE SPECIFIC ULTRASOUND PARAMETERS (AMPLITUDE, FREQUENCY, DUTY CYCLE, PULSE DURATION, AND TRANSDUCER GEOMETRY) THAT SEPARATELY OPTIMIZE BULK STREAMING AND MICROSTREAMING, WHILE AVOIDING HEMOLYSIS, INERTIAL CAVITATION, EXCESSIVE HEATING, AND BUBBLE GENERATION. AIM 2) DETERMINE THE MAXIMAL FIBER BUNDLE THICKNESS OVER WHICH ACOUSTIC STREAMING AND MICROSTREAMING ARE EFFECTIVE. AIM 3) FABRICATE AND EVALUATE A CUSTOM ULTRASOUND DELIVERY SYSTEM THAT SAFELY ENHANCES OXYGEN TRANSPORT BY AT LEAST SEVEN-FOLD. SUCCESSFUL RESULTS WILL NOT ONLY SHOW THE POTENTIAL OF US-ECMO BUT WILL PROVIDE THE NECESSARY DESIGN GUIDELINES TO DRIVE THE DEVELOPMENT OF A CLINICALLY VIABLE US-ECMO SYSTEM.

AEROSOL VENTILATION FOR RAPID COOLING OF TRANSPLANT DONOR LUNGS - PROJECT SUMMARY OVER 2,700 LUNG TRANSPLANTS ARE PERFORMED IN THE US EACH YEAR, BUT A SIGNIFICANT SHORTAGE OF DONOR LUNGS MEANS THAT THOUSANDS OF PEOPLE DIE EACH YEAR WHILE WAITING FOR A SUITABLE DONOR ORGAN. ALTHOUGH MOST DONOR LUNGS IN THE US ARE CURRENTLY TAKEN FROM BRAIN-DEAD DONORS, ONLY ~20% OF MULTIORGAN BRAIN DEAD DONORS PROVIDE SUITABLE LUNGS FOR TRANSPLANTATION. A SIGNIFICANT OPPORTUNITY FOR MORE DONOR LUNGS LIES WITH DONATION AFTER CARDIAC DEATH (DCD) DONORS, BUT ONLY A TINY FRACTION OF DCD DONORS IN THE US ARE USED FOR LUNG TRANSPLANTATION DUE TO CONCERNS OVER ISCHEMIC DAMAGE. LUNGS ARE CONSIDERED SIGNIFICANTLY INJURED FROM WARM ISCHEMIA IF THEY ARE NOT COOLED AND OXYGENATED WITHIN 60–90 MIN OF DIMINISHED PERFUSION OR OXYGENATION. IN ADDITION, LUNGS FROM DCD DONORS SUBJECT TO WARM ISCHEMIA FOR >60 MIN PRIOR TO PROCUREMENT HAVE IMPAIRED BRONCHIAL HEALING AND GREATER RISK OF PRIMARY GRAFT DYSFUNCTION OR REPERFUSION INJURY. AS SUCH, DEVELOPING A SIMPLE AND NON-INVASIVE METHOD OF COOLING AND OXYGENATING LUNGS IN POTENTIAL UNCONTROLLED DCD DONORS WOULD MITIGATE THE DAMAGING EFFECTS OF WARM ISCHEMIA WHILE THE DONOR IS PREPARED FOR PROCUREMENT AND PROVIDE A BOUNDLESS SUPPLY OF LUNG DONORS FROM THIS UNTAPPED DONOR POOL. TO IMPROVE THE POOL OF USABLE DONOR LUNGS, BOUNDLESS SCIENCE, LLC DEVELOPED A BI-LIQUID AEROSOLIZED VENTILATION (BAV) DEVICE PROTOTYPE THAT COOLS A LUNG QUICKLY AND EFFICIENTLY FOLLOWING DEATH. THE BAV AEROSOLIZES A MIXTURE OF TWO LIQUID PERFLUOROCARBONS (LP), INTRODUCES THE ATOMIZED DROPLETS INTO THE LUNGS THROUGH A VENTILATOR OR MASK, COLLECTS EVAPORATED LP VAPORS FROM THE LUNGS, CONDENSES AND OXYGENATES THE VAPOR, AND RETURNS THE COOLED LP LIQUID TO THE LUNGS VIA THE ORIGINAL AEROSOLIZATION METHOD. THE LP’S ENTHALPY OF VAPORIZATION PROVIDES RAPID COOLING WHILE ITS ABILITY TO CARRY OXYGEN PREVENTS HYPOXIC LUNG DAMAGE. THIS SAFE, EASY-TO-USE, PORTABLE DEVICE IS AMBULATORY AND CAN BE USED IN THE ICU AND THE ER TO NON-INVASIVELY COOL AND OXYGENATE LUNGS FOR TRANSPLANT WELL WITHIN AN HOUR AFTER DEATH. THE OBJECTIVE OF THIS PHASE 1 PROPOSAL IS TO PROVIDE PROOF OF CONCEPT THAT LUNGS CAN BE EFFICIENTLY COOLED FROM 37°C TO 20°C (TO DECREASE METABOLIC CONSUMPTION BY THE LUNGS WHILE PROVIDING OXYGEN TO THE AIRWAYS) IN <30 MIN USING A COMBINATION OF LPS. TO ACHIEVE EFFICIENT COOLING WITH BAV, WE BELIEVE THAT WE NEED TO INCORPORATE THE FOLLOWING OPTIMIZED PARAMETERS: DROPLET SIZE AND THEIR ALVEOLAR DWELL TIME, BOILING POINT OF THE LP MIXTURE, AND HEAT TRANSFER FLUID. THIS WILL BE ACHIEVED USING FOUR SPECIFIC AIMS. AIM 1: CREATE THE OPTIMAL DROPLET SIZE AND DENSITY TO EFFECTIVELY INFILTRATE ALVEOLI WITH AEROSOLIZED PERFLUOROPENTANE. AIM 2: BUILD AND EVALUATE AN EXHALED COOLING SYSTEM TO RECOVER THE VAPORIZED LP. AIM 3: DETERMINE THE OPTIMIZED MIXTURE OF LPS AND A CLINICALLY RELEVANT COOLING METHOD SUCH THAT PIG LUNGS CAN BE COOLED BY 17°C (TO 20°C) IN UNDER 30 MINUTES USING OPTIMIZED BAV PARAMETERS. AIM 4: MODIFY VENTILATOR SETTINGS TO MANIPULATE THE ALVEOLAR DWELL TIME OF LP DROPLETS. ONCE PROOF OF CONCEPT HAS BEEN OBTAINED, WE WILL PROGRESS TO PHASE II, WHERE WE WILL REFINE OUR PROTOTYPE DEVICE, TEST IT ON LIVE ANIMALS AND TEST FOR TISSUE HEALTH, AND PURSUE FDA APPROVAL.

EXTRA-CORPOREAL OXYGENATOR WITH MINIMAL BLOOD SURFACE CONTACT - PROJECT SUMMARY APPROXIMATELY 20,317 PATIENTS GLOBALLY RECEIVED ARTIFICIAL PULMONARY SUPPORT VIA EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) IN 2021. DURING ECMO, HOLLOW FIBER MEMBRANE (HFM) GAS EXCHANGERS REQUIRE A SURFACE AREA OF ~2 M2 TO ACHIEVE THERAPEUTIC GAS TRANSFER; HOWEVER, THIS LARGE CONTACT AREA WITH THE BLOOD ACTIVATES THE COAGULATION CASCADE THAT REQUIRES SYSTEMIC ANTICOAGULATION FOR SUPPRESSION, USUALLY WITH HEPARIN. ALTHOUGH HEPARIN REDUCES THE FREQUENCY OF CLOTTING, IT DOES NOT EFFECTIVELY INHIBIT THE SURFACE DEPOSITION OF PLATELETS AND PROTEINS. THE CONSUMPTION OF THESE CRITICAL CLOTTING COMPONENTS, AS WELL AS CONTINUOUS ADMINISTRATION OF SYSTEMIC ANTICOAGULANT, RESULTS IN AN INCREASED RISK OF BLEEDING DURING ECMO AND INCREASES THE RISK OF COMPLICATIONS AND MORTALITY. WE PROPOSE THAT REPLACING THE HFM GAS EXCHANGER WITH A LIQUID PERFLUOROCARBON BLOOD OXYGENATION SYSTEM WILL LEAD TO LESS CLOTTING AND REQUIRE LESS ANTICOAGULANT USE, REDUCING THE INCIDENCE OF BOTH THROMBOSIS AND HEMORRHAGE. LIQUID PERFLUOROCARBONS SUCH AS PERFLUORODECALIN (PFD) HAVE SEVERAL CHARACTERISTICS TO MAKE SUCH A SYSTEM VIABLE: (1) THEY ARE COMPLETELY IMMISCIBLE WITH BLOOD, ALLOWING EASY SEPARATION BETWEEN THE TWO LIQUIDS; (2) THEY HAVE ~TWICE THE DENSITY OF BLOOD, SUCH THAT BLOOD FLOWS UP THROUGH PERFLUOROCARBONS, MAKING A FLOW SYSTEM WORK THROUGH NATURAL CIRCULATION; (3) THEY CARRY ~40% OF THEIR WEIGHT IN OXYGEN AND >160% OF THEIR WEIGHT IN CARBON DIOXIDE, BOTH AT STP, ENABLING EFFICIENT GAS TRANSFER WITH BLOOD; AND (4) PFD IS SAFE IN THE HUMAN BODY HAVING BEEN APPROVED AS A BLOOD SUBSTITUTE IN 1989. BOUNDLESS WILL CREATE A DEVICE, A PERFLUOROCARBON BLOOD OXYGENATION SYSTEM (PBOS) THAT FLOWS OXYGENATED PFD INTO A CHAMBER IN COMBINATION WITH BLOOD USING VENTURI BLOOD DROPLET GENERATORS, NOZZLES THAT CREATE SMALL DROPLETS OF BLOOD WITH MINIMAL SHEAR, HEMOLYSIS, OR PLATELET ACTIVATION. THE SMALL BLOOD DROPLETS GAIN OXYGEN AND RELEASE CARBON DIOXIDE INTO THE PFD QUICKLY BEFORE REAGGLOMERATING AT THE TOP OF THE PBOS. THE NEWLY OXYGENATED BLOOD IS RETURNED TO THE BODY. THE PFD MOVES INTO A CHAMBER WHERE IT IS RE-OXYGENATED AND CARBON DIOXIDE IS REMOVED. THIS PROPOSAL SEEKS TO IDENTIFY AN OPTIMAL FLOW SYSTEM THAT OPTIMIZES EXTRACORPOREAL BLOOD OXYGENATION (AND CARBON DIOXIDE REMOVAL) WHILE PREVENTING BLOOD ACTIVATION, BLOOD DAMAGE, OR ADDING PFD TO THE BODY. IN REDUCING BLOOD SHEAR IN THE PBOS, WE WILL MINIMIZE HEMOLYSIS AND BLOOD ACTIVATION. WE WILL PROGRESS TOWARD THIS OBJECTIVE THROUGH THE FOLLOWING SPECIFIC AIMS: AIM 1: OPTIMIZE VDG GEOMETRY AND FLOW RATES THROUGH A COMBINATION OF IN-SILICO MODELING AND PROTOTYPES. AIM 2: QUANTIFY BLOOD OXYGENATION AND CO2 REMOVAL AS A FUNCTION OF DROPLET SIZES AND PFD FLOW RATES. AIM 3: DEMONSTRATE A 2 L/MIN SYSTEM WITH CLINICALLY USEFUL OXYGENATION, CO2 REMOVAL, AND HEMOLYSIS. AIM 4: DEVELOP PRELIMINARY MARKETING AND REGULATORY PLANS FOR THE PBOS. SUCCESSFUL RESULTS WILL NOT ONLY SHOW THE POTENTIAL OF PBOS BUT WILL PROVIDE THE NECESSARY DESIGN GUIDELINES TO DRIVE THE DEVELOPMENT OF A CLINICALLY VIABLE PBOS SYSTEM.

PURPOSE: TO SUPPORT THE TOURING PRODUCTION OF A STAGE ADAPTATION OF THE BOOK CRÓNICA DE UNA MUERTE ANUNCIADA (CHRONICLE OF A DEATH FORETOLD) BY GABRIEL GARCÍA MÁRQUEZ.

PURPOSE: TO SUPPORT THE PRODUCTION OF MERCADO LIBRE (FREE MARKET) BY LUIS ARAÚJO DIRECTED BY ISMANUEL RODRÍGUEZ.

TO SUPPORT THE MAINSTAGE PRODUCTION OF&NBSP;FUR BY PLAYWRIGHT MIGDALIA CRUZ.&NBSP;